Oncology Medical News about IGF2R polymorphisms, Esophageal, Gastric cancers

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas
International Journal of Cancer, 07/27/09

Hoyo C et al. - These findings suggest that nonsynonymous polymorphisms in mannose-6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) may contribute to the risks of esophageal and gastric adenocarcinomas (EGA) and noncardia adenocarcinomas. Larger studies are required to confirm these findings.

Methods

Study was conducted to test the hypothesis that the common nonsynonymous genetic variants in:
- M6P/IGF2R c.901C > G (Leu > Val) in exon 6, and
- c.5002G > A (Gly > Arg) in exon 34
  are associated with risk of EGA
Study participants: 197 controls and 182 cases, including:
- 105 with EGA
- 57 with noncardia gastric adenocarcinoma, and
- 20 with esophageal squamous (ES) cell carcinoma

Results

Among white males, odds ratios (ORs) were elevated in relation to carrying at least 1 c.901C > G allele for EGA and noncardia gastric cancer, but not ES
Exploratory subgroup analyses: associations between EGA and this variant were stronger among irregular or nonusers of NSAIDs and cigarette smokers
An association between carrying the c.5002G > A genotype and EGA was not evident

<< Previous
Identification of modifier genes for cutaneous malignant melanoma...

Next >>
Neutropenic fever syndromes in patients undergoing cytotoxic...